 Nilotinib is currently undergoing phase II studies for treatment of Parkinson's.Scientists and medical professionals have advised caution with over-optimistic interpretation of its effects in Parkinson's due to the significant media hype surrounding the small and early clinical trial.Dystonia and cognitive impairment have also been reported as side effects.